Match!
Kazuo Miyazawa
University of Birmingham
CardiologyAtrial fibrillationStrokeDiabetes mellitusMedicine
21Publications
3H-index
43Citations
What is this?
Publications 21
Newest
#1Daniele Pastori (University of Birmingham)H-Index: 23
#2Kazuo Miyazawa (University of Birmingham)H-Index: 3
Last. Gregory Y.H. Lip (University of Birmingham)H-Index: 143
view all 7 authors...
Background Patients with atrial high-rate episodes (AHREs) are at higher risk of thromboembolic events and mortality. The risk of major adverse cardiovascular events (MACE) in these patients is unknown.
2 CitationsSource
#1Kazuo Miyazawa (University of Birmingham)H-Index: 3
#2Hisashi OgawaH-Index: 10
Last. Gregory Y.H. Lip (University of Birmingham)H-Index: 143
view all 8 authors...
BACKGROUND:Guideline-adherent antithrombotic treatment (ATT) reduces the risk of stroke and death in patients with atrial fibrillation (AF). However, the effect of ATT adherence among different ethnicities remains uncertain. We compared the prognosis of AF patients in Japan and the UK according to guideline adherence status.Methods and Results:We compared the clinical characteristics and outcomes of AF patients from the Fushimi AF registry (Japan; n=4,239) and the Darlington AF registry (UK; n=2...
2 CitationsSource
#1Yan-Guang Li (University of Birmingham)H-Index: 4
#2Kazuo Miyazawa (University of Birmingham)H-Index: 3
Last. Gregory Y.H. Lip (University of Birmingham)H-Index: 143
view all 6 authors...
Abstract Background Patients with cardiac implantable electronic device (CIED) developing atrial high-rate episodes (AHRE) have a significant risk of thromboembolic events (TEs), but risk factors have been scarcely investigated. Objectives To analyze risk factors for TEs in a contemporary cohort of patients with CIED. Methods Consecutive non-AF patients without anticoagulation at baseline were followed up after the CIED implantation. The role of newly-developed AHRE and other risk factors for TE...
2 CitationsSource
#1Kazuo Miyazawa (University of Birmingham)H-Index: 3
#2Daniele Pastori (Sapienza University of Rome)H-Index: 23
Last. Gregory Y.H. Lip (University of Birmingham)H-Index: 143
view all 7 authors...
Background Atrial high rate episodes (AHREs) detected by cardiac implantable electronic devices (CIEDs) are associated with an increased risk of stroke. However, the impact of AHRE on improving stroke risk stratification scheme remains uncertain.
3 CitationsSource
#1Yan-Guang Li (University of Birmingham)H-Index: 4
#2Kazuo Miyazawa (University of Birmingham)H-Index: 3
Last. Gregory Y.H. Lip (University of Birmingham)H-Index: 143
view all 7 authors...
Abstract Background Differences exist in oral anticoagulation (OAC) use between different populations with atrial fibrillation (AF), which may be associated with varying outcomes. Purpose We aimed to provide patient level comparisons of clinical characteristics, OAC use, and one-year risks of stroke and mortality among two cohorts of patients with AF, from the United Kingdom (UK) and Middle East (ME). Methods The clinical characteristics, prescription of OAC, one-year risk of stroke and mortalit...
Source
#1Kazuo Miyazawa (University of Birmingham)H-Index: 3
#2Gregory Y.H. Lip (University of Birmingham)H-Index: 143
1 CitationsSource
#1Kazuo Miyazawa (University of Birmingham)H-Index: 3
#2Yan-Guang Li (Chinese PLA General Hospital)H-Index: 4
Last. Gregory Y.H. Lip (University of Birmingham)H-Index: 143
view all 7 authors...
Abstract Background Anticoagulation therapy in patients with atrial fibrillation (AF) is well established as effective thromboprophylaxis. However, AF patients with prior stroke are often treated with suboptimal antithrombotic treatment (ATT). In the present study, we investigated clinical characteristics and outcomes in AF patients with versus without prior stoke, in relation to guideline adherence in ATT. Methods We used data from the Gulf SAFE registry, which included patients with AF who pre...
2 CitationsSource
#1Orsolya Székely (University of Birmingham)H-Index: 2
#2Kazuo Miyazawa (University of Birmingham)H-Index: 3
Last. Gregory Y.H. Lip (University of Birmingham)H-Index: 143
view all 3 authors...
ABSTRACTIntroduction: Atrial fibrillation (AF) is associated with high morbidity and mortality rates due to thromboembolic complications, and anticoagulation is central to the management of this common arrhythmia to prevent acute thromboembolic events. The traditional anticoagulants: heparin, fondaparinux, and vitamin K antagonists (VKA, e.g. warfarin, acenocoumarol or phenprocoumin) have long served as pharmacotherapy for ischemic stroke prophylaxis.Areas covered: In this review article, the au...
Source
#1Kazuo Miyazawa (Birmingham City Hospital)H-Index: 3
#2Georges H. MairesseH-Index: 18
Last. Gregory Y.H. Lip (AAU: Aalborg University)H-Index: 143
view all 3 authors...
1 CitationsSource
#1Kazuo Miyazawa (University of Birmingham)H-Index: 3
#2Daniele Pastori (Sapienza University of Rome)H-Index: 23
Last. Francisco Marín (Ciber)H-Index: 45
view all 11 authors...
AbstractBackground: Non-vitamin K antagonist oral anticoagulants including rivaroxaban are widely used for stroke prevention in patients with atrial fibrillation (AF). We investigated the relationship between plasma biomarkers (indicative of thrombogenesis, fibrinolysis and inflammation) and left atrial thrombus resolution after rivaroxaban treatment.Methods: This was an ancillary analysis of the X-TRA study, which was a prospective interventional study evaluating the use of rivaroxaban for left...
1 CitationsSource
123